Health Systems Need to Use the New Tools to Address RSV, a Leading Cause of Baby Hospitalisations
Authors: Susan Hepworth & Leyla Kragten-Tabatabaie
From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs) and maternal vaccination, both recently recommended by the World Health Organization (WHO), could dramatically alter the RSV landscape.
Access to highly effective long-acting RSV-monoclonal antibodies for children in LMICs—reducing global inequity
Authors: Heather Zar et al.
More than 95% of RSV-associated deaths occur in LMICs, with more than two-thirds occurring outside a health facility. A strategy for preventing severe RSV-LRTI in infants in LMICs would have a major impact on child health given the high burden of disease, associated mortality, and limited access to health care. Two new strategies to prevent RSV-LRTI in infants and young children are now available.
This cross-sectional study assesses pediatricians’ knowledge, attitudes, and practices regarding RSV infection and emerging immunization strategies in Crete, Greece.While overall knowledge and vaccine confidence were high, important gaps were identified in...
Respiratory syncytial virus (RSV) vaccination is recommended in pregnancy. Limited data exist regarding antibody (Ab) durability to inform revaccination timing. They conducted prospective cohort studies among pregnant and older adults after first RSV vaccination in...
We compared the average population- based rates of hospitalization and the clinical features of the illness between boys and girls hospitalized with virologically confirmed RSV infection during 2006–2020 at Turku University Hospital, Finland. During this period,...
Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in healthy infants are needed.
Respiratory syncytial virus (RSV) is a leading cause of hospital admission for pneumonia in children <5 years of age, causing an estimated 100,000 childhood deaths each year [1]. Approximately 97 % of these deaths are estimated to occur in low- and middle-income...
Low- and middle-income countries (LMICs) bear the greatest burden of the global respiratory syncytial virus (RSV) morbidity and mortality, but lack cost data to evaluate the health-economic impact of RSV burden on families, the healthcare system, and society. This...
Duration of protection after respiratory syncytial virus (RSV) vaccination is unknown. This study aimedto evaluate efficacy and safety over three RSV seasons of the AS01E-adjuvanted RSV prefusion F protein-based vaccine(RSVPreF3 OA) against RSV-related lower...
Respiratory Syncytial Virus (RSV) is a relatively frequent cause of serious respiratory illness in older adults and those with pre-existing medical conditions.[1,2] The burden of RSV in adults is estimated to account for 60-180,000 hospitalizations and 10,000-14,000...
We did a prospective cohort study in primary care settings in Belgium, Italy, Spain, the Netherlands, and the UK during the RSV seasons of 2020–21 (UK only; from Jan 1, 2021), 2021–22, and 2022–23. Children aged younger than 5 years presenting to their general...
Respiratory syncytial virus (RSV) is the second most common pathogen causing infant mortality. Additionally, RSV is a major cause of morbidity and mortality in older adults (age ≥60 years) similar to influenza. A protein-based maternal vaccine and monoclonal antibody...
In April, 2024, we reported on mid-season findings from NIRSE-GAL, a population-based longitudinal study on the effectiveness of universal nirsevimab prophylaxis against respiratory syncytial virus (RSV) in infants aged 0–24 months in Galicia, Spain. Our early...
Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that Ziresovir may have efficacy in the treatment of infants hospitalized with RSV infection. Ziresovir treatment...